Quick Answer
X4 Pharmaceuticals, Inc reported Operating Income of -$86.88 million for fiscal year 2025.
X4 Pharmaceuticals, Inc Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$86.88M | -138.7% |
| 2024 | -$36.40M | +66.1% |
| 2023 | -$107.52M | -22.8% |
| 2022 | -$87.57M | -2.9% |
| 2021 | -$85.11M | -42.1% |
| 2020 | -$59.87M | -15.8% |
| 2019 | -$51.70M | -77.8% |
| 2018 | -$29.09M | -30.7% |
| 2017 | -$22.25M | +8.6% |
| 2016 | -$24.35M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$27.51M | +20.3% | -4.9% |
| June 30, 2025 | -$26.23M | -136.9% | -177.8% |
| March 31, 2025 | -$9.44M | +74.7% | +72.6% |
| September 30, 2024 | -$34.50M | -26.8% | -148.5% |
| June 30, 2024 | $71.10M | +375.5% | +290.7% |
| March 31, 2024 | -$37.29M | -27.2% | -37.0% |
| September 30, 2023 | -$27.21M | -35.0% | -5.5% |
| June 30, 2023 | -$25.80M | -25.4% | +11.9% |
- X4 Pharmaceuticals, Inc showed a decrease of -138.7% in Operating Income compared to the prior fiscal year.
- Over the 2016–2025 period, X4 Pharmaceuticals, Inc’s operating income has declined by 256.9% (from -$24.35 million to -$86.88 million).
- The most recent figure is from X4 Pharmaceuticals, Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: